In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Genzyme acquires Bone Care International for $600mm

Executive Summary

Genzyme has acquired Bone Care International (vitamin D-hormone therapy for serious diseases) for $33 per share, which equates to about $600mm in cash. The purchase price, which is net of Bone Care's $119mm cash and cash equivalents that it will return to Genzyme, is almost 14 times Bone Care's 2004 revenues, and represents a 34% premium to the company's trading average.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Intra-Biotech Deal
    • Payment Includes Cash

Related Companies